摘要
目的探讨雷帕霉素洗脱支架(SES)在急性ST段抬高性心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)中的近、远期疗效及安全性。方法226例确诊为STEMI患者分为金属裸支架(BMS)组(n=98)和SES组(n=128),分别植入BMS和SES,对比观察术后30 d内及30 d^1年两组主要心脏事件(MACE)[心脏性死亡、非致死性心肌梗死、靶血管再次血运重建率(TVR)]的发生率。结果术后30 d内两组MACE发生率差异无统计学意义(P>0.05)。与BMS组相比,术后30 d^1年SES组MACE发生率显著降低(分别为5.7%和14.9%,P<0.01),主要与TVR显著降低有关(分别为3.3%和11.7%,P<0.01);两组间再次非致死性心肌梗死(分别为0.8%和1.1%)及心脏性死亡(分别为1.6%和2.1%)的发生率差异无统计学意义(均P>0.05)。结论STEMI患者采用SES治疗1年内疗效明显优于BMS,两者安全性相似;长期疗效及安全性还需要进一步临床研究证实。
Objective To assess efficacy and safty of sirolimus-eluting stents(SES) in patients with ST-segment elevation acute myocardial infarction(STEMI).Methods From January 2003 to June 2006,226 patients with STEMI underwent primary percutaneous coronary intervention(PCI),128 were treated with sirolimus-eluting stents(SES) and 98 were treated with bare metal stent(BMS).In-hospital,within 30 days and 30 days to one-year after PCI major adverse cardiovascular events(MACE) were recoreded and compared between the two groups.Results The incidence of MACE was similar between SES group and BMS group within 30 days after primary PCI.At one-year,compared with BMS group,MACE rate was significantly lower in SES group(5.7% vs 14.9%,P<0.01),mainly due to a marked reduction in the risk of target vessel revascularation(TVR 3.3% vs 11.7%,P<0.01).Cardiac death and myocardial infarction(MI) rate were similar between SES group and BMS group.Conclusion The current one-year data indicate that treatment of STEMI using SES is safe and more effective compared with using BMS.It′s long-term efficacy and safety need to be futher investigated.
出处
《现代医学》
2007年第6期436-438,共3页
Modern Medical Journal
